Neuronetics is a privately held company developing non-invasive treatments for depression and other chronic psychiatric and neurological disorders based upon neuromodulation technology. On September 1, 2010, the World Economic Forum announced the company as a Technology Pioneer for 2011.

Property Value
dbo:abstract
  • Neuronetics is a privately held company developing non-invasive treatments for depression and other chronic psychiatric and neurological disorders based upon neuromodulation technology. On September 1, 2010, the World Economic Forum announced the company as a Technology Pioneer for 2011. (en)
dbo:foundingYear
  • 2003-01-01 (xsd:date)
dbo:industry
dbo:location
dbo:numberOfEmployees
  • 120 (xsd:integer)
dbo:product
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 15865186 (xsd:integer)
dbo:wikiPageRevisionID
  • 743744393 (xsd:integer)
dbp:keyPeople
  • Christopher Thatcher, President & CEO
  • Mark Bausinger, Chief Financial Officer
  • Mark Demitrack MD, Chief Medical Officer
  • Judy Ways, Ph.D., VP, Regulatory Affairs & Quality Assurance
  • Stanford Miller, VP, New Business Development
dbp:logo
  • 170 (xsd:integer)
dbp:wordnet_type
dct:subject
rdf:type
rdfs:comment
  • Neuronetics is a privately held company developing non-invasive treatments for depression and other chronic psychiatric and neurological disorders based upon neuromodulation technology. On September 1, 2010, the World Economic Forum announced the company as a Technology Pioneer for 2011. (en)
rdfs:label
  • Neuronetics (en)
owl:sameAs
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Neuronetics, Inc. (en)
is dbo:wikiPageRedirects of
is foaf:primaryTopic of